Pathology and Treatment of Triple-Negative Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 462
Special Issue Editor
Interests: pancreatic, breast and liver cancer prevention and treatment; anti-cancer agents from natural products; tumor suppression; integrative cancer treatment; health care disparities; therapeutic/prognostic marker identification
Special Issue Information
Dear Colleagues,
We are pleased to announce the call for submissions to a Special Issue of the journal Cancers titled, 'Pathology and Treatment of Triple-Negative Breast Cancer'. Triple-negative breast cancer (TNBC) represents a distinct subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This aggressive form of breast cancer poses significant challenges in diagnosis, treatment, and management.
This Special Issue aims to provide a comprehensive overview of the current knowledge and advancements in TNBC, from its underlying pathology to innovative treatment strategies. We invite researchers, clinicians, and experts in the field of breast cancer research and oncology to submit their original research articles, reviews, and clinical studies that cover various aspects of TNBC including, but not limited to, the following:
- Molecular and genetic profiling of TNBC;
- Novel biomarkers and diagnostic approaches;
- Insights into the tumor microenvironment and immune response;
- Targeted therapies and immunotherapies for TNBC;
- Advancements in surgical techniques and radiation therapy.
All submitted articles will undergo a rigorous peer review process to ensure their highest scientific quality and relevance to the field.
Should you have any questions, require further information, or need any assistance, please do not hesitate to contact us.
We look forward to receiving your submissions.
Dr. Ramadevi Subramani
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
